[go: up one dir, main page]

IS2819B - Viðloðunarsameindir í æðum og mótun á starfsemi@þeirra - Google Patents

Viðloðunarsameindir í æðum og mótun á starfsemi@þeirra

Info

Publication number
IS2819B
IS2819B IS6072A IS6072A IS2819B IS 2819 B IS2819 B IS 2819B IS 6072 A IS6072 A IS 6072A IS 6072 A IS6072 A IS 6072A IS 2819 B IS2819 B IS 2819B
Authority
IS
Iceland
Prior art keywords
adhesion molecules
formulation
activity
vascular adhesion
cram
Prior art date
Application number
IS6072A
Other languages
English (en)
Other versions
IS6072A (is
Inventor
Beat Albert Imhof
Michel Aurrand-Lions
Original Assignee
Serono Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Serono Lab filed Critical Serono Lab
Publication of IS6072A publication Critical patent/IS6072A/is
Publication of IS2819B publication Critical patent/IS2819B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IS6072A 1999-03-11 2001-09-10 Viðloðunarsameindir í æðum og mótun á starfsemi@þeirra IS2819B (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP99200746 1999-03-11
PCT/EP2000/002219 WO2000053749A2 (en) 1999-03-11 2000-03-13 Vascular adhesion molecules and modulation of their function

Publications (2)

Publication Number Publication Date
IS6072A IS6072A (is) 2001-09-10
IS2819B true IS2819B (is) 2012-12-15

Family

ID=8239973

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6072A IS2819B (is) 1999-03-11 2001-09-10 Viðloðunarsameindir í æðum og mótun á starfsemi@þeirra

Country Status (22)

Country Link
US (3) US7393651B2 (is)
EP (2) EP2292761A1 (is)
JP (2) JP4836329B2 (is)
CN (2) CN1637019A (is)
AT (1) ATE500328T1 (is)
AU (1) AU782139B2 (is)
BR (1) BR0008915A (is)
CA (1) CA2362896C (is)
CZ (1) CZ303128B6 (is)
DE (1) DE60045681D1 (is)
EE (1) EE05497B1 (is)
ES (1) ES2361905T3 (is)
HU (1) HU229376B1 (is)
IL (1) IL145310A0 (is)
IS (1) IS2819B (is)
MX (1) MXPA01009110A (is)
NO (1) NO333085B1 (is)
NZ (1) NZ514091A (is)
PL (1) PL207994B1 (is)
RU (1) RU2244748C2 (is)
WO (1) WO2000053749A2 (is)
ZA (1) ZA200107283B (is)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8007798B2 (en) 1997-11-21 2011-08-30 Genentech, Inc. Treatment of complement-associated disorders
US8088386B2 (en) 1998-03-20 2012-01-03 Genentech, Inc. Treatment of complement-associated disorders
EP2292761A1 (en) * 1999-03-11 2011-03-09 Merck Serono S.A. Vascular adhesion molecules and modulation of their function
GB0100750D0 (en) * 2001-01-11 2001-02-21 Inpharmatica Ltd Novel proteins
WO2003006673A2 (en) * 2001-07-11 2003-01-23 Texas Biotechnology Corporation A nucleic acid encoding a human junctional adhesion protein (jam3)
US7642341B2 (en) 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
EP1533617A1 (en) * 2003-11-19 2005-05-25 RMF Dictagene S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment and diagnosis of cancer
KR20180002911A (ko) 2005-11-04 2018-01-08 제넨테크, 인크. 안질환 치료를 위한 보체 경로 억제제의 용도
RU2464030C2 (ru) * 2006-05-26 2012-10-20 Регадо Байосайенсиз, Инк. Введение противосвертывающей системы reg1
JP2010504955A (ja) 2006-09-28 2010-02-18 メルク セローノ ソシエテ アノニム 接合部接着分子ｃ（ｊａｍ−ｃ）結合化合物とその利用方法
CL2007003161A1 (es) 2006-11-02 2008-05-30 Genentech Inc Anticuerpos anti-factor d; acidos nucleicos que los codifican; vector y linea celular que los comprenden; metodo de produccion; composicion farmaceutica que comprende a los anticuerpos; y su uso para tratar trastornos mediados por el complemento como
FR2909092B1 (fr) * 2006-11-24 2012-10-19 Pf Medicament Nouveaux anticorps anti-proliferation
AR066660A1 (es) 2007-05-23 2009-09-02 Genentech Inc Prevencion y tratamiento de condiciones del ojo asociadas con su complemento
US8772257B2 (en) * 2007-08-06 2014-07-08 Noxxon Pharma Ag SDF-1 binding nucleic acids and the use thereof
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
BR112016002845A2 (pt) 2013-08-12 2017-09-12 Genentech Inc composições e métodos para tratar condições associadas ao complemento
EP3137503A1 (en) 2014-05-01 2017-03-08 Genentech, Inc. Anti-factor d antibody variants and uses thereof
WO2017075252A1 (en) 2015-10-30 2017-05-04 Genentech, Inc. Anti-factor d antibody variant conjugates and uses thereof
JP2018534930A (ja) 2015-10-30 2018-11-29 ジェネンテック， インコーポレイテッド 抗ｄ因子抗体及びコンジュゲート

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000053753A2 (en) * 1999-03-08 2000-09-14 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
US20030170864A1 (en) * 2000-05-30 2003-09-11 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
SE9604470D0 (sv) * 1996-12-04 1996-12-04 Tamas Bartfai Konsulting Ab Transmembrane component of tight junction
WO1998040483A2 (en) * 1997-03-14 1998-09-17 Human Genome Sciences, Inc. 28 human secreted proteins
CA2283631A1 (en) * 1997-03-21 1998-10-01 Genetics Institute, Inc. Secreted proteins and polynucleotides encoding them
ES2287979T3 (es) 1997-08-01 2007-12-16 Serono Genetics Institute S.A. Est 5' para proteinas secretadas identificadas a partir de tejidos cerebrales.
US20030077654A1 (en) 1997-09-17 2003-04-24 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1002864A1 (en) 1998-11-10 2000-05-24 Universita' degli studi di Bologna HIgR and related V domain for the manufacture of a medicament for preventing or treating HSV-1, HSV-2 and BHV infections
EP1141285A2 (en) * 1998-12-16 2001-10-10 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP2292761A1 (en) * 1999-03-11 2011-03-09 Merck Serono S.A. Vascular adhesion molecules and modulation of their function
US7642341B2 (en) 2003-12-18 2010-01-05 Merck Serono S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
EP1533617A1 (en) * 2003-11-19 2005-05-25 RMF Dictagene S.A. Angiogenesis inhibiting molecules, their selection, production and their use in the treatment and diagnosis of cancer

Also Published As

Publication number Publication date
PL207994B1 (pl) 2011-02-28
US7393651B2 (en) 2008-07-01
JP4836329B2 (ja) 2011-12-14
HUP0200606A3 (en) 2004-11-29
IL145310A0 (en) 2003-01-12
WO2000053749A3 (en) 2000-12-14
AU4105100A (en) 2000-09-28
JP2010233572A (ja) 2010-10-21
MXPA01009110A (es) 2002-08-20
WO2000053749A2 (en) 2000-09-14
CN1637019A (zh) 2005-07-13
CZ20013267A3 (cs) 2002-02-13
HK1044169A1 (en) 2002-10-11
EP2292761A1 (en) 2011-03-09
NO333085B1 (no) 2013-02-25
RU2244748C2 (ru) 2005-01-20
CA2362896A1 (en) 2000-09-14
EP1163337A2 (en) 2001-12-19
US20050266426A1 (en) 2005-12-01
NZ514091A (en) 2004-01-30
US7670826B2 (en) 2010-03-02
US20080274970A1 (en) 2008-11-06
EP1163337B1 (en) 2011-03-02
EE200100472A (et) 2002-12-16
NO20014417D0 (no) 2001-09-11
BR0008915A (pt) 2002-04-09
HUP0200606A2 (en) 2002-06-29
CN1355843A (zh) 2002-06-26
PL350417A1 (en) 2002-12-16
CN100469878C (zh) 2009-03-18
ES2361905T3 (es) 2011-06-24
DE60045681D1 (de) 2011-04-14
US8143056B2 (en) 2012-03-27
NO20014417L (no) 2001-11-12
ZA200107283B (en) 2002-12-24
JP2002537837A (ja) 2002-11-12
ATE500328T1 (de) 2011-03-15
HU229376B1 (en) 2013-11-28
AU782139B2 (en) 2005-07-07
CA2362896C (en) 2012-07-31
US20100267649A1 (en) 2010-10-21
IS6072A (is) 2001-09-10
EE05497B1 (et) 2011-12-15
CZ303128B6 (cs) 2012-04-18

Similar Documents

Publication Publication Date Title
IS2819B (is) Viðloðunarsameindir í æðum og mótun á starfsemi@þeirra
DE68929043D1 (de) Für androgen-rezeptor-protein kodierende dna
DK0910647T3 (da) Human DNase i hyperaktive varianter
DE69427650D1 (de) Verbindungen mit wachstumshormon-freisetzenden eigenschaften
DK1025124T3 (da) Human interferon-alfa-analoge med lav toksicitet
NO873699D0 (no) Polypeptid som er egnet til dempning, behandling og diagnosering av autoimmune lidelser saasom leddbetennelser.
DE60331546D1 (de) Verwendung von aspartic proteasen in den bereichen kosmetik und behandlung
ATE294236T1 (de) Promotor der tie rezeptor protein kinase
RU94041224A (ru) Пептиды с органозащитной активностью, фармацевтическая композиция на их основе и их применение в терапии
HUT66309A (en) Bpc peptides, their preparation and therapeutic use
FI893681A0 (fi) N-2,3-butadienyltri- och tetra-aminoalkanderivat.
ES2177625T3 (es) Citoquina cc-1 humana circulante.
BR9007115A (pt) Novo trombolitico
NO993653D0 (no) Fremgangsmåte for diagnose, prognose og behandling av glaukom og relaterte sykdommer
MX9203175A (es) Composicion de implante que contiene un peptido, polipeptido o proteina biologicamente activa y procedimiento para su preparacion.
ES2073391T3 (es) Metodo y composiciones terapeuticas para el tratamiento de trastornos de perdidas de sangre.
DE69737293D1 (de) Nukleotidsequenz, die für eine flavinmonooxygenase kodiert, das korrespondierende protein, sowie deren verwendungen in diagnostik und therapie
DE69836278D1 (de) Allele formen von menschlichem stat3
KR100488038B1 (ko) 기관 보호 활성을 지닌 신규한 신체 보호 화합물 펩티드염, 이의 제조 방법 및 치료에서의 이의 용도
DK0870036T3 (da) Syntetisk pattedyrs-alfa-N-acetylglucosaminidase og genetiske sekvenser kodende derfor
EP0832109A4 (en) FACTOR-2, HOMOLOGY OF THE FIBROBLASTS GROWTH FACTOR AND METHOD FOR ITS APPLICATION
DE3777359D1 (de) Aminosaeuresequenz des menschlichen alpha 2-plasmininhibitors und cdns sowie diese aminosaeuresequenz codierende genomische dns.
DK0423326T3 (da) Hidtil ukendt fysiologisk aktivt peptid og calcium-metabolisme-regulerende middel, der omfatter peptidet som effektiv besta
WO1998056810A3 (de) Humanes protein lus-i, seine herstellung und verwendung
IT8621261A0 (it) Composizioni farmaceutiche per la terapia di stati fisiopatologici ad accresciuto catabolismo proteico.